THE COLOPHON
About Order Wolverine
A reading that keeps the BPC-157 TB-500 record the way an apothecary keeps a formulary — each component drawn as its own specimen, the measured findings set down plainly, the regulatory status kept in the margin.
What this site is
Order Wolverine keeps a formulary for the BPC-157 TB-500 blend — the peer-reviewed research literature and the public FDA regulatory record, drawn up together. There is no clinic here and no clinician on staff; no diagnosis, no dose guidance, and no medical advice are given; and nothing is compounded, stocked, or supplied. What is set down is a reading of published science and public regulatory documents, cited throughout.
The apothecary conceit is deliberate. The Wolverine blend is treated as what it actually is — a two-component pairing whose individual parts carry measured records and whose join does not. Established single-component findings are inked as fully drawn specimens; the unproven combination and the missing human data are left in the warm margin as open questions. The honesty lives in how the record is laid out, not in a caveat tucked at the end.
What "order" means here
The word "order" in the name is a reading term — not a checkout, not a service on offer. It marks the apothecary order of the record: the formulary order, the considered ledger of what has been studied and where access actually stands. It is the stance this publisher takes toward the literature, not a claim about anything sold or supplied.
No treatment, consultation, prescription, or sale is offered here, and neither medical nor legal advice is given. Everything on these pages is general information about the published science and the public regulatory landscape. Where the regulatory record is unsettled — as it is, with both components currently in FDA's 503A Category 2 and under a scheduled 2026 committee review — that is stated plainly, and no outcome is ever presented as decided or dated.
How we handle the evidence
Every quantitative claim on this site is tied to a numbered citation in the full reference list with PMIDs and DOIs: the peer-reviewed component studies, the 2025-2026 systematic reviews, and the FDA sources. We do not present rodent results as human expectations, we do not present a fixed-ratio vial as a validated dose, and we do not present the marketed synergy as proven — because no controlled combination study exists.
Where the literature is strong, we say so: BPC-157's transected-Achilles tendon data and VEGFR2-Akt-eNOS angiogenesis are well characterized, and Thymosin Beta-4's migration and wound-healing activity is consolidated in review. Where it is thin or absent — human combination efficacy, combination safety, a defined synergy ratio — we mark the gap rather than paper over it. That is the whole editorial posture: a careful reading of a two-part record, kept the way a specimen folio is kept.